Literature DB >> 19218020

Diagnosis and management of the primary headache disorders in the emergency department setting.

Benjamin Wolkin Friedman1, Brian Mitchell Grosberg.   

Abstract

Headache continues to be a frequent cause of emergency department (ED) use, accounting for 2% of all visits. Most of these headaches prove to be benign but painful exacerbations of chronic headache disorders, such as migraine, tension-type, and cluster. The goal of ED management is to provide rapid and quick relief of benign headache, without causing undue side effects, and to recognize headaches with malignant course. Although these headaches have distinct epidemiologies and clinical phenotypes, there is overlapping response to therapy; nonsteroidals, triptans, dihydroergotamine, and the antiemetic dopamine antagonists may play a therapeutic role for each of these acute headaches. This article reviews the diagnostic criteria and management strategies for the primary headache disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19218020      PMCID: PMC2676687          DOI: 10.1016/j.emc.2008.09.005

Source DB:  PubMed          Journal:  Emerg Med Clin North Am        ISSN: 0733-8627            Impact factor:   2.264


  97 in total

1.  Slow infusion for the prevention of akathisia induced by prochlorperazine: a randomized controlled trial.

Authors:  D R Vinson; A F Migala; C P Quesenberry
Journal:  J Emerg Med       Date:  2001-02       Impact factor: 1.484

2.  The symptom of headache in emergency departments. The experience of a neurology emergency department.

Authors:  E Luda; R Comitangelo; L Sicuro
Journal:  Ital J Neurol Sci       Date:  1995-06

3.  Medication use and disability among migraineurs: a national probability sample survey.

Authors:  D D Celentano; W F Stewart; R B Lipton; M L Reed
Journal:  Headache       Date:  1992-05       Impact factor: 5.887

4.  An evaluation of the role of the ED in the management of migraine headaches.

Authors:  J A Salomone; R W Thomas; J R Althoff; W A Watson
Journal:  Am J Emerg Med       Date:  1994-03       Impact factor: 2.469

5.  Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study.

Authors:  B E Akpunonu; A B Mutgi; D J Federman; F G Volinsky; K Brickman; R L Davis; C Gilbert; M Asgharnejad
Journal:  Ann Emerg Med       Date:  1995-04       Impact factor: 5.721

6.  Ketorolac versus meperidine-plus-promethazine treatment of migraine headache: evaluations by patients.

Authors:  C P Davis; P R Torre; C Williams; C Gray; K Barrett; G Krucke; D Peake; B Bass
Journal:  Am J Emerg Med       Date:  1995-03       Impact factor: 2.469

7.  Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: a randomized, prospective, double-blind trial.

Authors:  C Duarte; F Dunaway; L Turner; J Aldag; R Frederick
Journal:  Ann Emerg Med       Date:  1992-09       Impact factor: 5.721

8.  A randomized, double-blind, comparative study of the efficacy of ketorolac tromethamine versus meperidine in the treatment of severe migraine.

Authors:  G L Larkin; J E Prescott
Journal:  Ann Emerg Med       Date:  1992-08       Impact factor: 5.721

9.  A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.

Authors:  P Winner; O Ricalde; B Le Force; J Saper; B Margul
Journal:  Arch Neurol       Date:  1996-02

10.  Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches.

Authors:  J A Klapper; J S Stanton
Journal:  Headache       Date:  1991-09       Impact factor: 5.887

View more
  17 in total

1.  Comparison of parenteral treatments of acute primary headache in a large academic emergency department cohort.

Authors:  Lucas H McCarthy; Robert P Cowan
Journal:  Cephalalgia       Date:  2014-11-03       Impact factor: 6.292

Review 2.  Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache.

Authors:  Sheridan M Hoy; Lesley J Scott
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

3.  Understanding of headache patterns modification in an emergency department during the economic crisis of Greece.

Authors:  Anastasia Bougea; Nicolaos Spantideas; Evangelos Anagnostou; Efthalia Massou; Sophia Xirou; Thomas Thomaidis; Ioannis Evdokimidis; Evangelia Kararizou
Journal:  Neurol Sci       Date:  2016-04-08       Impact factor: 3.307

4.  Diagnosis of acute headache.

Authors:  Stephanie J Nahas
Journal:  Curr Pain Headache Rep       Date:  2011-04

5.  Management of headache disorders in the Emergency Department setting.

Authors:  Elisa Pari; Fabrizio Rinaldi; Stefano Gipponi; Elisabetta Venturelli; Paolo Liberini; Renata Rao; Alessandro Padovani
Journal:  Neurol Sci       Date:  2015-03-10       Impact factor: 3.307

Review 6.  Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.

Authors:  Stephen D Silberstein; Shashidhar H Kori
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

7.  The presenting and prescribing patterns of migraine in an Australian emergency department: A descriptive exploratory study.

Authors:  Emily Shao; James Hughes; Rob Eley
Journal:  World J Emerg Med       Date:  2017

8.  Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan.

Authors:  Benjamin W Friedman; Clemencia Solorzano; David Esses; Shujun Xia; Michael Hochberg; Niels Dua; Alan Heins; Paul Sasso; Polly E Bijur; Richard B Lipton; E John Gallagher
Journal:  Ann Emerg Med       Date:  2010-03-19       Impact factor: 5.721

9.  Optimal management strategies for primary headache in the emergency department.

Authors:  Simon Wells; Ian G Stiell; Evgeniya Vishnyakova; Ronda Lun; Marie-Joe Nemnom; Jeffrey J Perry
Journal:  CJEM       Date:  2021-08-14       Impact factor: 2.410

10.  A Retrospective Cohort Study of Urgent Care Visits and Revisits for Headache/Migraine.

Authors:  Mia Minen; Kina Zhou; Ramona Lall; Benjamin W Friedman
Journal:  Pain Med       Date:  2020-10-01       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.